Management of immune checkpoint inhibitor‐related dermatologic adverse events

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. The unique spectrum of immune‐related adverse events (IrAEs) may occur during treatment. Dermatologic toxicities appear to be one of the most prevalent immunotherapy‐related adverse events. The most common symptoms are maculop...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Thorac Cancer
Egile Nagusiak: Si, Xiaoyan, He, Chunxia, Zhang, Li, Liu, Xiaowei, Li, Yue, Wang, Hanping, Guo, Xiaoxiao, Zhou, Jiaxin, Duan, Lian, Wang, Mengzhao
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons Australia, Ltd 2019
Gaiak:
Clinical Guideline
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6997012/
https://ncbi.nlm.nih.gov/pubmed/31814310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13275
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak